June 29, 2020 / 9:00 PM / 5 days ago

BRIEF-Genmab Announces Very Favorable Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

June 29 (Reuters) - Genmab A/S:

* GENMAB ANNOUNCES VERY FAVORABLE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

* GENMAB A/S - GENMAB, SEATTLE GENETICS PLAN TO DISCUSS PHASE 2 INNOVATV 204 RESULTS WITH U.S. FDA

* GENMAB A/S - RESULTS FROM INNOVATV 24 TRIAL SHOWED 24% CONFIRMED ORR BY INDEPENDENT CENTRAL REVIEW Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below